From treatment to trend, slimming drug boom sparks misuse concerns

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

The surge in weight-loss injections across India, particularly among young women chasing rapid slimming ahead of weddings or other special events, is raising alarm among doctors, who are calling for tighter medical oversight as cheaper semaglutide generics expand access to GLP-1 therapies and heighten concerns over cosmetic misuse.

 

The fast-growing GLP-1 market, propelled by lower-cost generics following patent expiry, is widening availability beyond patients with obesity and diabetes -- but also driving unsupervised, appearance-led demand, according to doctors. BNP Paribas estimates the market at around ₹1,000 crore, with strong growth expected as prices fall, though adoption remains concentrated in tier-1 and tier-2 cities.

 

The lapse of Novo Nordisk’s semaglutide patent has triggered one of the most crowded drug rollouts in India’s recent pharmaceutical history. More than 40-50 branded generics are expected, with prices 50-90 per cent lower than innovator levels. Some Indian versions are now priced from about ₹1,290 per month, a fraction of earlier costs.

 

Dr Shashank Shah, a bariatric surgeon at Apollo Spectra Hospital in Pune, said falling prices and social media are accelerating demand, especially among younger women seeking rapid results. While these drugs -- many originally developed for diabetes -- can suppress appetite and support weight management, he cautioned they are not universally appropriate and require careful evaluation of body composition, health status and underlying causes of weight gain. Side effects such as nausea, dizziness, indigestion, fatigue and constipation are common, he added, stressing that sustainable weight control still depends on diet, exercise, sleep and stress management.

 

Dr Aparna Govil Bhasker, consultant bariatric surgeon at MetaHeal Clinic and Namaha Hospitals in Mumbai, underscored that GLP-1 therapies are prescription medicines designed to treat obesity as a disease, not tools for cosmetic slimming. They are typically indicated for patients with a BMI above 30, or above 27 with related co-morbidities, and require ongoing monitoring as they can alter diabetes and hypertension treatment needs. “They are not meant for cosmetic weight loss. Indiscriminate use can lead to complications,” she said.

 

Dr Bhasker warned that misuse may result in gastrointestinal distress, nutritional deficiencies, muscle loss, gallstones and, in rare cases, pancreatitis. She pointed to mounting social pressure, particularly around weddings, as a key driver, with unrealistic beauty standards, amplified by social media, pushing women towards short-term medical fixes.

 

The concerns echo findings from recent Lancet studies, which note that while GLP-1 therapies are reshaping obesity care globally, broader uptake demands careful long-term monitoring, especially in Asian populations, where metabolic risks arise at lower BMI thresholds. In India, doctors say the priority is clear: Ensuring that wider access through cheaper generics does not slide into reckless self-medication or vanity-driven use outside clinical care.

 

Disciplined scaling

 

What studies suggest:

 

> A 2024 study in The Lancet EClinicalMedicine highlights the rapid global adoption of GLP-1 receptor agonists, emphasising the need for robust long-term safety monitoring, especially as use expands beyond clinical obesity.

 

> A 2024 analysis in The Lancet Diabetes & Endocrinology finds that Asian populations face metabolic risks at lower BMI levels than Western populations, underscoring the importance of physician-led screening and careful patient selection in countries like India.